$166 Million

Pliant Therapeutics

Initial Public Offering

Bookrunner, June 2020

Pliant Therapeutics

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. The Company’s lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of αvβ6 and αvβ1 integrins that is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company’s second product candidate, PLN-1474, is an oral small molecule selective inhibitor of αvβ1 for stage F3/F4 liver fibrosis associated with nonalcoholic steatohepatitis (NASH).